Dynamic modeling for pandemic influenza

References

• Postma MJ, Milne G, Nelson EA et al.; PI Group. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. Expert Rev. Anti Infect. Ther. 8(12), 1431–1439 (2010).
   PubMed Web of Science ®Google Scholar
• Lugnér AK, Postma MJ. Investment decisions in influenza pandemic contingency planning: cost–effectiveness of stockpiling antiviral drugs. Eur. J. Public Health 19(5), 516–520 (2009).
   PubMed Web of Science ®Google Scholar
• Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26(29–30), 3742–3749 (2008).
   PubMed Web of Science ®Google Scholar
• Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA 103(15), 5935–5940 (2006).
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerging Infect. Dis. 5(5), 659–671 (1999).
   PubMed Web of Science ®Google Scholar
• Chien YW, Levin BR, Klugman KP. The anticipated severity of a “1918-like” influenza pandemic in contemporary populations: the contribution of antibacterial interventions. PLoS ONE 7(1), e29219 (2012).
   Web of Science ®Google Scholar
• Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26, 3742–3749 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature 318(6044), 323–329 (1985).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448–452 (2006).
   PubMed Web of Science ®Google Scholar
• de Vries R, Kretzschmar M, Schellekens JF et al. Cost–effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010).
   PubMed Web of Science ®Google Scholar
• Hubben G, Bootsma M, Luteijn M et al. Modelling the costs and effects of selective and universal hospital admission screening for methicillin-resistant Staphylococcus aureus. PLoS ONE 6(3), e14783 (2011).
   PubMed Web of Science ®Google Scholar
• Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 28(12), 2370–2384 (2010).
   PubMed Web of Science ®Google Scholar
• Mossong J, Hens N, Jit M et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5(3), e74 (2008).
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Edmunds WJ. Cost–effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerging Infect. Dis. 14(2), 267–274 (2008).
   PubMed Web of Science ®Google Scholar
• van Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in The Netherlands: scenario analysis. Emerging Infect. Dis. 9(5), 531–538 (2003).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Heijnen ML, Jager JC. Cost–effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 19(2), 215–222 (2001).
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325(21), 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Health Council. Commissie vaccinatie tegen influenza. Caccinatie bij een griep pandemie. Gezondheidsraad, Den Haag, The Netherlands (2000).
   Google Scholar
• Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 29(5), 371–386 (2011).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Bos JM, Beutels P, Schilthuis H, van den Hoek JA. Pharmaco–economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 22(15–16), 1862–1867 (2004).
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost–effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27(9), 1454–1467 (2009).
   PubMed Web of Science ®Google Scholar
• Lugnér AK, Postma MJ. Mitigation of pandemic influenza: review of cost–effectiveness studies. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 547–558 (2009).
   PubMedGoogle Scholar
• Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12(2), 226–233 (2009).
   PubMed Web of Science ®Google Scholar